Human AML cells were used as the immunogen for this CD33 antibody.
This antibody recognizes a 67kDa glycoprotein, which is identified as CD33 (HLDA IV, WS Code M-505). CD33 is a transmembrane protein of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. It belongs to the immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing molecules able of recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to signal assemblies, these ITIMs are also used for ubiquitin-mediated removal of the receptor from the cell surface. CD33 is expressed on cells of myelomonocytic lineage, binds sialic acid residues in N- and O-glycans on cell surfaces, and is a therapeutic target for acute myeloid leukemia. CD33 is expressed on myeloid progenitors, monocytes, granulocytes, dendritic cells and mast cells. It is absent on platelets, lymphocytes, erythrocytes and hematopoietic stem cells.
Klonalität:
Monoclonal
Konzentration:
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
Target-Kategorie:
CD33
Antibody Type:
Primary Antibody
Application Verdünnung:
Flow cytometry: 1-2ug/10 6 cells
Anwendungsbeschreibung:
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CD33 antibody to be titered up or down for optimal performance.1. Not suitable for use in FFPE IHC testing.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
